1. Home
  2. NTNX vs IBRX Comparison

NTNX vs IBRX Comparison

Compare NTNX & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nutanix Inc.

NTNX

Nutanix Inc.

HOLD

Current Price

$40.87

Market Cap

10.1B

Sector

Technology

ML Signal

HOLD

Logo ImmunityBio Inc.

IBRX

ImmunityBio Inc.

HOLD

Current Price

$7.31

Market Cap

8.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTNX
IBRX
Founded
2009
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.1B
8.4B
IPO Year
2015
2015

Fundamental Metrics

Financial Performance
Metric
NTNX
IBRX
Price
$40.87
$7.31
Analyst Decision
Buy
Strong Buy
Analyst Count
17
7
Target Price
$64.33
$12.57
AVG Volume (30 Days)
3.1M
23.0M
Earning Date
02-25-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
227.45
38.71
EPS
0.57
N/A
Revenue
$2,537,927,000.00
$113,288,000.00
Revenue This Year
$13.60
$88.59
Revenue Next Year
$13.18
$131.15
P/E Ratio
$66.75
N/A
Revenue Growth
18.11
668.31
52 Week Low
$35.39
$1.83
52 Week High
$83.36
$12.43

Technical Indicators

Market Signals
Indicator
NTNX
IBRX
Relative Strength Index (RSI) 54.67 46.24
Support Level $35.84 $5.89
Resistance Level $42.50 $8.28
Average True Range (ATR) 1.70 0.94
MACD 0.06 -0.21
Stochastic Oscillator 72.79 25.50

Price Performance

Historical Comparison
NTNX
IBRX

About NTNX Nutanix Inc.

Nutanix Inc is engaged in cloud software, offering organizations a single platform for running applications and managing data anywhere. Its Nutanix Cloud Platform is designed to enable organizations to build a hybrid multicloud infrastructure, providing a consistent cloud operating model with a single platform for running applications and managing data in core data centers, at the edge, and in public clouds, all while supporting a variety of hypervisors and container platforms. The company operates a single operating and reportable segment based on a subscription business model. It conducts business in the United States, Europe, the Middle East and Africa, Asia Pacific, and other Americas, with key revenue generated from the United States.

About IBRX ImmunityBio Inc.

ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.

Share on Social Networks: